Antibe Therapeutics Inc. (ATBPF) は上場企業です ヘルスケア セクターの Medical - Devices 業界で事業展開. 本社所在地は Toronto, ON, カナダ. 現CEOは Daniel Marcel Legault.
ATBPF を有する IPO日 2014-10-09, 11 名の正社員, に上場 Other OTC, 時価総額 $11.43M.
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.
